Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

Vincent Rijckborst, Bettina E. Hansen, Peter Ferenci, Maurizia R. Brunetto, Fehmi Tabak, Yilmaz Cakaloglu, A. Galeota Lanza, Vincenzo Messina, Claudio Iannacone, Benedetta Massetto, Loredana Regep, Massimo Colombo, Harry L A Janssen, Pietro Lampertico

Research output: Contribution to journalArticle

121 Citations (Scopus)

Abstract

Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

Original languageEnglish
Pages (from-to)1006-1011
Number of pages6
JournalJournal of Hepatology
Volume56
Issue number5
DOIs
Publication statusPublished - May 2012

Fingerprint

Hepatitis B e Antigens
Hepatitis B Surface Antigens
DNA
Serum
peginterferon alfa-2a

Keywords

  • HBV genotype
  • HBV therapy
  • Immunomodulator
  • Nucleos(t)ide analogues
  • Peginterferon
  • Quantitative HBsAg

ASJC Scopus subject areas

  • Hepatology

Cite this

Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. / Rijckborst, Vincent; Hansen, Bettina E.; Ferenci, Peter; Brunetto, Maurizia R.; Tabak, Fehmi; Cakaloglu, Yilmaz; Lanza, A. Galeota; Messina, Vincenzo; Iannacone, Claudio; Massetto, Benedetta; Regep, Loredana; Colombo, Massimo; Janssen, Harry L A; Lampertico, Pietro.

In: Journal of Hepatology, Vol. 56, No. 5, 05.2012, p. 1006-1011.

Research output: Contribution to journalArticle

Rijckborst, V, Hansen, BE, Ferenci, P, Brunetto, MR, Tabak, F, Cakaloglu, Y, Lanza, AG, Messina, V, Iannacone, C, Massetto, B, Regep, L, Colombo, M, Janssen, HLA & Lampertico, P 2012, 'Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a', Journal of Hepatology, vol. 56, no. 5, pp. 1006-1011. https://doi.org/10.1016/j.jhep.2011.12.007
Rijckborst, Vincent ; Hansen, Bettina E. ; Ferenci, Peter ; Brunetto, Maurizia R. ; Tabak, Fehmi ; Cakaloglu, Yilmaz ; Lanza, A. Galeota ; Messina, Vincenzo ; Iannacone, Claudio ; Massetto, Benedetta ; Regep, Loredana ; Colombo, Massimo ; Janssen, Harry L A ; Lampertico, Pietro. / Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. In: Journal of Hepatology. 2012 ; Vol. 56, No. 5. pp. 1006-1011.
@article{b4f1cd0ac2d545629d27be30ce40c8ba,
title = "Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a",
abstract = "Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with",
keywords = "HBV genotype, HBV therapy, Immunomodulator, Nucleos(t)ide analogues, Peginterferon, Quantitative HBsAg",
author = "Vincent Rijckborst and Hansen, {Bettina E.} and Peter Ferenci and Brunetto, {Maurizia R.} and Fehmi Tabak and Yilmaz Cakaloglu and Lanza, {A. Galeota} and Vincenzo Messina and Claudio Iannacone and Benedetta Massetto and Loredana Regep and Massimo Colombo and Janssen, {Harry L A} and Pietro Lampertico",
year = "2012",
month = "5",
doi = "10.1016/j.jhep.2011.12.007",
language = "English",
volume = "56",
pages = "1006--1011",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier B.V.",
number = "5",

}

TY - JOUR

T1 - Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a

AU - Rijckborst, Vincent

AU - Hansen, Bettina E.

AU - Ferenci, Peter

AU - Brunetto, Maurizia R.

AU - Tabak, Fehmi

AU - Cakaloglu, Yilmaz

AU - Lanza, A. Galeota

AU - Messina, Vincenzo

AU - Iannacone, Claudio

AU - Massetto, Benedetta

AU - Regep, Loredana

AU - Colombo, Massimo

AU - Janssen, Harry L A

AU - Lampertico, Pietro

PY - 2012/5

Y1 - 2012/5

N2 - Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

AB - Background & Aims: It was recently demonstrated that none of the hepatitis B e antigen (HBeAg)-negative patients without any serum hepatitis B surface antigen (HBsAg) decline and with

KW - HBV genotype

KW - HBV therapy

KW - Immunomodulator

KW - Nucleos(t)ide analogues

KW - Peginterferon

KW - Quantitative HBsAg

UR - http://www.scopus.com/inward/record.url?scp=84859734382&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859734382&partnerID=8YFLogxK

U2 - 10.1016/j.jhep.2011.12.007

DO - 10.1016/j.jhep.2011.12.007

M3 - Article

VL - 56

SP - 1006

EP - 1011

JO - Journal of Hepatology

JF - Journal of Hepatology

SN - 0168-8278

IS - 5

ER -